CO2022012476A2 - Hidrato cristalino de un compuesto inhibidor de jak - Google Patents

Hidrato cristalino de un compuesto inhibidor de jak

Info

Publication number
CO2022012476A2
CO2022012476A2 CONC2022/0012476A CO2022012476A CO2022012476A2 CO 2022012476 A2 CO2022012476 A2 CO 2022012476A2 CO 2022012476 A CO2022012476 A CO 2022012476A CO 2022012476 A2 CO2022012476 A2 CO 2022012476A2
Authority
CO
Colombia
Prior art keywords
crystalline hydrate
inhibitor compound
jak inhibitor
hydrate
crystalline
Prior art date
Application number
CONC2022/0012476A
Other languages
English (en)
Inventor
Gene Timothy Fass
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CO2022012476A2 publication Critical patent/CO2022012476A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En el presente documento se proporciona un hidrato cristalino del compuesto de fórmula 1. También se proporcionan en este documento composiciones farmacéuticas que comprenden dicho hidrato cristalino, métodos para usar dicho hidrato cristalino para tratar enfermedades respiratorias y procesos útiles para preparar dicho hidrato cristalino.
CONC2022/0012476A 2020-03-02 2022-08-31 Hidrato cristalino de un compuesto inhibidor de jak CO2022012476A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983931P 2020-03-02 2020-03-02
PCT/US2021/070207 WO2021178991A1 (en) 2020-03-02 2021-03-01 Crystalline hydrate of a jak inhibitor compound

Publications (1)

Publication Number Publication Date
CO2022012476A2 true CO2022012476A2 (es) 2022-09-20

Family

ID=75143791

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012476A CO2022012476A2 (es) 2020-03-02 2022-08-31 Hidrato cristalino de un compuesto inhibidor de jak

Country Status (16)

Country Link
US (2) US11702415B2 (es)
EP (1) EP4114836A1 (es)
JP (1) JP2023516640A (es)
KR (1) KR20220149585A (es)
CN (1) CN115190878A (es)
AR (1) AR121483A1 (es)
AU (1) AU2021232100A1 (es)
BR (1) BR112022017398A2 (es)
CA (1) CA3172338A1 (es)
CL (1) CL2022002368A1 (es)
CO (1) CO2022012476A2 (es)
IL (1) IL295613A (es)
MX (1) MX2022010795A (es)
TW (1) TW202144343A (es)
WO (1) WO2021178991A1 (es)
ZA (1) ZA202209617B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210056381A (ko) * 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
PL3001903T3 (pl) 2009-12-21 2018-03-30 Samumed, Llc 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
CA3037243A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1 h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
KR20180073687A (ko) 2015-11-03 2018-07-02 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물
WO2017077288A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US20180258546A1 (en) 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
EA037748B1 (ru) 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Конденсированные имидазо-пиперидиновые ингибиторы jak
EP3619208B1 (en) 2017-05-01 2023-06-07 Theravance Biopharma R&D IP, LLC Crystalline forms of a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
KR20210056381A (ko) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
TWI808250B (zh) 2018-09-04 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 用於製備jak抑制劑之方法及其中間體
JP2022506111A (ja) 2018-10-29 2022-01-17 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物
PE20212069A1 (es) 2019-02-25 2021-10-26 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物

Also Published As

Publication number Publication date
JP2023516640A (ja) 2023-04-20
CA3172338A1 (en) 2021-09-10
CL2022002368A1 (es) 2023-04-21
AU2021232100A1 (en) 2022-10-20
US20240025897A1 (en) 2024-01-25
WO2021178991A1 (en) 2021-09-10
US11702415B2 (en) 2023-07-18
US20210269437A1 (en) 2021-09-02
IL295613A (en) 2022-10-01
KR20220149585A (ko) 2022-11-08
ZA202209617B (en) 2023-04-26
MX2022010795A (es) 2022-11-30
EP4114836A1 (en) 2023-01-11
AR121483A1 (es) 2022-06-08
BR112022017398A2 (pt) 2022-10-18
TW202144343A (zh) 2021-12-01
CN115190878A (zh) 2022-10-14

Similar Documents

Publication Publication Date Title
CO2022012476A2 (es) Hidrato cristalino de un compuesto inhibidor de jak
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
NI201800093A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer
DOP2023000168A (es) Compuestos antivirales que contienen nitrilo
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
MX2019000123A (es) Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores.
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
CL2020001754A1 (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
ECSP21016009A (es) Inhibidores de sarcómeros cardíacos
AR066972A1 (es) Derivados azapeptidicos
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY38665A (es) Agentes antiproliferativos para el tratamiento de pah
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
AR123285A1 (es) Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
BR112023003744A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2